Cannasoul Analytics
Medical Cannabis Analytics
Company Overview
Snapshot
Founded in January 2018 by Prof. David (Dedi) Meiri and Shmuel (Muli) Mandel, Cannasoul Analytics operates with 11–50 employees. The company has secured $4M in total capital raised across two funding rounds from two investors. In November 2023, Synaptogenix acquired a significant stake in the company.
Business overview
Cannasoul Analytics is an Israeli cannabis drug-discovery company focused on developing therapeutics derived from natural compounds. The company utilizes a proprietary analytical platform and a data-driven approach, combined with its expertise and clinical trial framework, to identify and develop active compounds from botanical extracts through to clinically approved formulations. Cannasoul Analytics serves the health tech and life sciences sector, specifically operating within the pharmaceutical, medical cannabis, and biotechnology industries.
Strategic signal
In November 2025, Cannasoul Analytics entered into strategic investment and collaboration agreements with InterCure to advance cannabis science and pharmaceutical innovation. This partnership signals a significant validation of Cannasoul's drug discovery platform and its potential to contribute to the development of new cannabis-derived therapeutics, indicating a strong forward trajectory in the medical cannabis and pharmaceutical markets.
Company Intelligence Q&A
- What is Cannasoul Analytics' primary focus?
- Cannasoul Analytics is an Israeli cannabis drug-discovery company developing therapeutics derived from natural compounds, leveraging its analytical platform and data-driven approach for active compound identification and formulation.
- When was Cannasoul Analytics founded and by whom?
- Cannasoul Analytics was founded in January 2018 by Prof. David (Dedi) Meiri and Shmuel (Muli) Mandel.
- What was a key strategic development for Cannasoul Analytics in November 2025?
- In November 2025, Cannasoul Analytics signed strategic investment and collaboration agreements with InterCure to advance cannabis science and pharmaceutical innovation.
- Which company acquired a significant stake in Cannasoul Analytics in November 2023?
- In November 2023, Synaptogenix acquired a significant stake in Cannasoul Analytics.
- What was the nature of the collaboration between Eybna and Cannasoul Analytics in April 2020?
- In April 2020, Eybna and Cannasoul Analytics joined forces to prove a proprietary terpene formulation for treating viral infections by modulating cytokine storm.